69 results about "Intracellular calcium ion" patented technology

The present invention provides a peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and / or a non-amino acid compound, or a pharmaceutically acceptable salt thereof.

The American ginseng milk is compounded with American ginseng, milk, thickener, stabilizer, butter and sugar and through mixing. The present invention has the positive effects of restoring brain from fatigue, delaying senility of brain, regulating fat metabolism, lowering cholesterol, preventing the motor fatigue and damage caused by free radical induction, regulating absorption and blocking of calcium ion on cell membrane and avoiding the negative effect of accumulation of calcium ion inside cell.

The invention relates to an amantadine nitrate compound with a neuroprotective effect, and preparation therefor and medical application thereof. The compound has a structure of a general formula (I) as shown in the specification, has multimechanisms, comprises NMDA receptor inhibition, NO releasing and inhibition of inward flow of calcium ions, and has a good protection effect on cells, particularly on neurons. The compound can be used for preparing drugs with a cytoprotection effect, and the drugs are used for preventing or treating diseases related to increasing of NMDA receptors, calcium ions in cells and the like, such as diseases related to neurodegeneration including senile dementia, parkinson's disease, brain stroke, glaucoma and the like, diseases related to a cardio-cerebrovascular system including parkinsonism combined with cerebral arteriosclerosis, and respiratory tract infectivity caused by influenza viruses.

The present invention relates to stilbene glycosie compound and the use of its derivative and medicinal salt in preparing medicine for dementia, especially for Alzheimer disease and vascular dementia. Animal experiment proves that stilbene glycoside compound can resist brain cell damage caused by beta-amyloid protein and hydrogen peroxide, raise the memory capacity of mouse model with scopolaminedementia and A beta dementia and gerbille model with double-sided common carotid artery obstruction caused brain ischemia, inhibit the lipide peroxidation of brain tissue of mouse model with brain ischemia, strengthen the activity of its brain tissue SOD, and reduce the calcium ion density in its brain cells.

The invention belongs to the field of antibody drug, and discloses a full human-derived anti-human VEGFR2 monoclonal antibody screened by a phage antibody base technology and prepared by a gene engineering method, and further discloses a carrier including polynucleotide for encoding the monoclonal antibody, a host cell and an application. Through combining with VEGFR2, the monoclonal antibody stops the combination of VEGF with VEGR2, and does not induce receptor dimerization, cause the following tyrosine residue phosphorylation in intracellular tyrosine kinase structure and activate downstream signal access including activation of phospholipase C and increase of calcium ion concentration in the cell and others; the antibody drug triggers endothelial proliferation, survival, cytoskeleton rearrangement, cell migration, gene expression and others, and finally stops the vascular proliferation caused by combination of VEGF and VEGFR2 and induction of dimerization. The monoclonal antibody can be used for treating diseases caused by tumor angiogenesis.

The invention provides a microfluidic chip group used for screening a formyl peptide receptor agonist and a screening method. The microfluidic chip group consists of three microfluidic chip units, i.e. a cell chemotaxis detection unit, a receptor endocytosis detection unit and a calcium ion transient flow process monitoring unit. The invention designs a group of chips by aiming to the characteristics of different cell function analytical experiments, can respectively carry out cell chemotaxis, receptor endocytosis detection and calcium ion transient flow (release) process monitoring, and judges biologic activity thereof by comprehensively evaluating influence on the formyl peptide receptor signal conduction path by an alternative compound. Compared with the traditional technology, the invention realizes real-time monitoring of the intracellular calcium ion releasing process and saves a series of complex operations, such as film laying, film obtaining, cell doctoring, fixing, dying andthe like, thereby greatly saving the analysis time and lowering the detection cost.

A calcineurin activator, comprising the following protein (a) or (b) as an active ingredient and having the action of increasing intracellular calcium ion concentration through the influx of calcium ions into eukaryotic cells: (a) a killer protein (KLKP), being composed of 3 subunits consisting of amino acid sequences represented by SEQ ID NOS: 2, 3, and 4, respectively, and being produced by Kluyveromyces lactis killer yeast; or (b) a protein, being the same as protein (a) except for differing from protein (a) in that at least one of the 3 subunits consists of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2, 3, or 4 by deletion, substitution, or addition of 1 or several amino acids, and having Kluyveromyces lactis killer protein (KLKP) activity.

The present invention relates to pharmaceutical uses of a Na<+>-coupled HCO3< > transporter (NBC1) N-cyano amide sulfide inhibitor S0859, and provides uses of a Na<+>-coupled HCO3< > transporter (NBC1) N-cyano amide sulfide inhibitor S0859 in preparation of heart failure treating drugs. According to the present invention, the results prove that the inhibitor S0859 can regulate the intracellular calcium ion homeostasis after myocardial infarction, improve ventricular remodeling, and inhibit intracellular calcium overload so as to inhibit ventricular remodeling, such that the invention can provide a new heart failure treating drug so as to effectively delay heart failure and ventricular remodeling caused by myocardial infarction.

The present invention relates to a preventive or a therapeutic agent for hepatopathy, comprising, as an effective ingredient, a polypeptide derivative having an activity of binding to growth hormone secretagogue receptor and thus elevating intracellular calcium ion concentration, and having one amino acid sequence selected from the group consisting of amino acid sequences represented by SEQ ID NOS: 1 to 22, or an amino acid sequence in which one to several amino acids are deleted, substituted or added at the amino acid residues other that the first to forth amino acid residues from the amino-terminus in the said amino acid sequence, or a pharmacologically acceptable salt thereof. The preventive or the therapeutic agent for hepatopathy in accordance with the present invention is useful as a drug suitable for treating or preventing hepatic diseases such as hepatitis, liver cirrhosis and hepatic insufficiency. Further, the preventive or the therapeutic agent for hepatopathy in accordance with the present invention is also useful as an agent of promoting hepatic regeneration and hepatic function recovery after hepatectomy.

The invention provides American ginseng milk and a preparation method thereof, and relates to a milk prepared product. The American ginseng milk is mixed by American ginseng extracting solution, milk with thickening agent and the like. The invention has the beneficial effects that the brain fatigue can be resumed, the brain insenescence can be delayed, the lipid metabolism can be mediated, the blood cholesterol can be reduced, the unavailable blood cholesterol reduction function caused by the low-choline content in new milk can be recovered, the kinetic fatigue damage caused by free radicals can be avoided, and the absorbing and the blocking of the calcium ions on the cell membrane can be adjusted, so that the side effects caused by the accumulation of the calcium ions in the cells can be avoided.

The invention discloses a 1,3,4-oxadiazole derivative and a synthetic method thereof, and an application of the derivative serving as a fluorescent indicator to detection of intracellular calcium ions (Ca<2+>). The method comprises the following steps of: under the protection of inert gas, performing a wittig reaction on the 1,3,4-oxadiazole derivative and a calcium ion response group to obtain a crude product; and concentrating the crude product, and separating through a silica gel column to obtain a pure product. The 1,3,4-oxadiazole derivative has the advantages of high sensitivity and high selectivity on Ca<2+>, large Stocks displacement, proportional measurement and the like; the color of the indicator changes greatly before and after bonding with Ca<2+>, so that identification and judgment can be performed conveniently through naked eyes; and moreover, the indicator can be loaded into cells, so that an intracellular Ca<2+> signal and the concentration thereof can be detected conveniently under a laser confocal microscope.

The invention relates to the technical field of 1,2,4-triazole heterocyclic compounds and discloses application of a 1,2,4-triazole heterocyclic compound in the preparation of drugs to prevent or treat central system related diseases. The 1,2,4-triazole heterocyclic compound [1,2,4]-triazolo-[1,5-a]pyrimidone heterocyclic compound shown as the general formula (I) or 7-alkoxy-1,2,4-triazolo-[1,5-a]pyrimidine heterocyclic compound shown as the general formula (II). The 1,2,4-triazole heterocyclic compound disclosed herein can well inhibit, on cellular models, intracellular calcium ion oscillations and 4-AP induced epilepsy, and on animal models (mouse), has good anti-epilepsy activity and significant calming effect.

The invention relates to an antibacterial antistatic PS composite material and a preparation method thereof. The antibacterial antistatic PS composite material is prepared from the following components in parts by weight: 80-100 parts of PS, 4-6 parts of an antibacterial agent, 4-8 parts of modified graphene and 0.1-0.5 part of an antioxidant, wherein the antibacterial agent is a praseodymiumPr ion antibacterial agent. Pr ions have the function of antagonizing intracellular calcium ions, and calcium ions are ions maintaining the normal physiological activities of cells, so that the Pr ions caninterfere with the normal life activities of bacterial cells and cause bacterial death. Through the addition of the special antibacterial agent, the antibacterial property of the PS composite material is enhanced; and through the addition of the modified graphene, the improvement on the antistatic property of the PS composite material is facilitated.

The present disclosure provides fluorogenic compounds useful for preparing fluorescent calcium ion indicators, the fluorescent indicators themselves, and the use of the fluorescent indicators in methods of detection, discrimination and quantification of metal ions. The subject fluorogenic compounds and fluorescent ion indicators can include a chelating group based on a 2-aminophenoxyethylene glycol 2-aminoethyl ether, N,N,N′,N′-tetraacetic acid (PEGTA) moiety or precursor thereof where the phenyl group of the PEGTA is substituted with or fused with a fluorophore moiety of interest. The subject methods find use in the detection of intracellular calcium ions. Also provided are kits for use in practicing the subject methods.

The present disclosure provides a light-activated, calcium-gated polypeptide; and a system comprising: a) the light-activated, calcium-gated polypeptide; and b) a fusion protein comprising a calcium responsive polypeptide and a protease that cleaves a proteolytically cleavable linker present in the light-activated, calcium-gated polypeptide. The present disclosure provides nucleic acids encoding the light-activated, calcium-gated polypeptide or the system, and cells comprising the nucleic acids. The present disclosure provides methods of detecting a change in intracellular calcium ion concentration. The present disclosure provides methods of controlling or modulating an activity of a cell.

The invention provides a quantitative method for determining sweetness at a cellular level. The quantitative method for determining the sweetness at the cellular level includes various steps such as intracellular calcium ion fluorescence staining, laser confocal scanning, microscopic determination of intracellular calcium ion concentration changes. The quantitative method for determining the sweetness at the cellular level has the advantages of establishing a method for studying the intracellular calcium ion concentration changes of sweet receptor cells by using fluorescence detection technology, conducting quantitative perception of the sweetness of other unknown samples by humans in vitro, effectively avoiding the influence of human subjective factors, being fast, efficient, and highly sensitive in the detection of compound sweetness, and having a good application prospect.

The invention provides an aquaculture composite microbial preparation and a preparation method thereof, and belongs to the field of biochemistry. The aquaculture composite microbial preparation comprises 15-30 wt% of tea seed cakes, 10-30 wt% of sesame seed meal, 10-30 wt% of brown sugar, 2-3 wt% of an enzyme and bacterium mixture, 5-15 wt% of Commelina communis and 15-30 wt% of limewater. The aquaculture composite microbial preparation can promote secretion of digestive enzymes in shrimps, stimulate the glucosamine to rapidly run to form a new shell, accelerate effective absorption of mineralelements, inhibit release of calcium ions from smooth muscle endoplasmic reticulum, reduce the concentration of calcium ions in cells, excite central nerves, expand blood vessels, increase the musclecontractility and improve the anti-stress and anti-osmotic pressure effects, so crustacean aquatic animals can be stimulated to smoothly shell.

The invention provides a cell model and a screening method for screening a calcium-activated chloride ion channel inhibitor. The screening method sequentially comprises the steps of (1) constructing eukaryotic expression vectors of Anoctamin1 or Anocatmin2 and YFP-H148Q / I152L; (2) stably transfecting the two vectors into FRT (Fisher rat thyroid) cells respectively to ensure that the RFT cells co-express two proteins of YFP-H148Q / I152l and Anoctamin1 or Anocatmin2, and performing multiple times of limiting dilution to obtain an FRT cell model; (3) transferring the FRT cell model to a black-wall microporous plate with a black wall and a transparent bottom; (4) adding a small molecular compound to be detected into the black-wall microporous plate, incubating, then adding a regent for raising the concentration of calcium ions in cells and high-concentration iodide ions, and screening the calcium-activated chloride channel inhibitor by detecting the change of relative fluorescence intensity.

A regulator for regulating physiological functions, such as activity of increasing an intracellular calcium ion concentration, activity of promoting growth hormone secretion, activity of promoting eating, regulatory activity relating to fat accumulation, activity of ameliorating heart function and activity of stimulating gastric acid secretion, of ghrelin, which regulator comprises a fatty acid of carbon number 2-35 or its derivative, and use thereof.

A fluorescent probe for calcium ion detection that has an excellent photofading resistance and quick Ca2+ detection kinetics and can be localized at an arbitrary site in a cell is provided. The fluorescent probe contains a compound represented by the following general formula (I) or a salt thereof:A method for detecting intracellular calcium ions including (a) introducing the compound above or a salt thereof into a cell and (b) measuring the fluorescence emitted by the compound or a salt thereof in the cell is also provided.

The invention discloses a Panx3 gene overexpression red fluorescence lentiviral vector and a building method and application of the Panx3 gene overexpression red fluorescence lentiviral vector, and belongs to the field of gene engineering. According to the vector, a lentiviral vector pLL3.7 is used as a skeleton vector, a Panx3 gene, CMV promoter and RFP gene segment is inserted behind a CMV promoter of pLL3.7 in the direction from the 5' end to the 3' end, and the sequence of the segment is shown in SEQIDNO.1. The built Panx3 gene overexpression red fluorescence lentiviral vector has the advantages that the mutual interference problem of the overexpression vector and function research in Panx3 gene research is solved, a CMV serves as the promoter of the vector, eukaryon gene efficient expression can be guaranteed, RFP serves as a marker, the role of the Panx3 gene in intracellular calcium and ATP change after a half-channel is formed can be directly observed, the cell function is eventually affected, and a good tool is provided for research on the functions of the Panx3 gene.

The invention provides a hydroxy fatty acid oligomer and an application of the hydroxy fatty acid oligomer in adjusting the growth of cells and improving the concentration of calcium ions in the cells. As proved by experiments, the hydroxy fatty acid oligomer can inhibit the proliferation of cancer cells, induce the apoptosis and the death of the cells, prolong the G1 period of the cells and reduce the segmentation degree of the cancer cells. As shown by the further calcium imaging technical detection, the oligomer also can stimulate the increase of the concentration of dissociative calcium ions in the cells.

The subject invention relates to improved tocopheryl quinone derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage Disorders, restoration of normal mitochondrial ATP production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms.

A 3,4-dihydroquinazoline derivative or a pharmaceutically acceptable salt thereof and a composition containing the same are provided. The 3,4-dihydroquinazoline derivative or a pharmaceutically acceptable salt thereof show activities of blocking an intracellular influx of calcium ions acting as a secondary signal essential to the proliferation and growth of cancer cells, thereby inducing the cell cycle arrest of cancer cells, and eventually reinforcing the efficacy of existing anti-cancer drugs. A combination comprising the above compound and another anti-cancer drug is also provided.

The present invention relates to a preparation method for an antibacterial agent. The method comprises the following steps: weighing a certain amount of praseodymium oxide, deionized water, nitric acid, and hydrogen peroxide, and adding the materials to a reaction vessel to form Pr(NO3)3.6H2O; weighing a certain amount of sodium 2-hydroxyphenylacetate, ethanol, deionized water, 5-chloro-7-hydroxyquinoline, and Pr(NO3)3.6H2O, performing a reaction on the materials to obtain a solution A; adjusting a pH value of the solution A with nitric acid or sodium hydroxide, and performing steps of washing, pumping filtration, drying, grinding, and sieving to obtain the antibacterial agent. The Pr ion has the function of antagonizing intracellular calcium ions, and calcium ions are ions that maintain the normal physiological activity of cells, which interfere with the normal life activities of bacterial cells and cause bacterial death; the addition of the special antibacterial agent enhances the antibacterial properties of polymer composites, and the antibacterial agent has great promotion value.

The invention provides a preparation method for responsive nanoparticles with a mitochondrion-targeted function. The method comprises the steps: S1) mixing an inorganic calcium salt, dopamine and an alcohol solvent, so as to obtain a precursor solution; and S2) placing the precursor solution and ammonium bicarbonate in a closed environment in a noncontact manner, and carrying out heating for a reaction, so as to obtain the responsive nanoparticles. Compared with the prior art, the responsive nanoparticles prepared by the method has the advantages that the responsive nanoparticles are uniform in shape and uniform in size, have relatively high thermal stability and chemical stability, can achieve excited response of a variety of light of different wavelengths, can continuously generate calcium ions in tumor cells to increase a concentration of the calcium ions in the cells, and can also cooperate with micromolecular drugs to inhibit a calcium ion discharging action of a mitochondrion andcooperate with the micromolecular drugs to jointly destroy functions of the mitochondrion so as to promote damage of the mitochondrion, and thus, the aim of tumor therapy is achieved, so that the responsive nanoparticles have great potentials in cancer therapy in the future.

The present invention is directed to methods of treating a subject, wherein a biological sample taken from the subject comprises an antibody against a small protein encoded by an intermediate stage transcript of HHV-6 (SITH-1), and the antibody against SITH-1 being present in an amount sufficient to be detected in the biological sample which is at least diluted 10-fold or more by an immunological detection method. Such treatment methods are used for the following: a) treating or preventing mood disorders; b) suppressing an elevation of the level of SITH-1 within cells in the subject's brain, reducing the number of cells in the brain that carry the protein SITH-1, and / or reducing the total amount of SITH-1 in the brain; c) suppressing an elevation of the level of a calcium modulating cyclophilin ligand (CAML) protein within cells in the subject's brain; or d) suppressing an elevation of the level of calcium ions within cells in the subject's brain. Methods of the present invention can involve administering a human herpesvirus 6 suppressor to a subject.